News for AVEO Stock

CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) LG Chem Completes Acquisition of AVEO Oncology AVEO Oncology Stockholders Approve Acquisition by LG Chem AVEO Oncology Reminds Stockholders to Vote “FOR” All-Cash Transaction with LG Chem in advance of the Special Meeting of Stockholders AVEO Oncology Reports Third Quarter 2022 Financial Results LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced Renal Cell Carcinoma AVEO Oncology Announces Participation at the Cantor Fitzgerald Oncology & HemOnc Conference AVEO Oncology Announces Participation at Investor Conferences in September AVEO Oncology Reports Second Quarter 2022 Financial Results AVEO Oncology to Announce Second Quarter 2022 Financial Results on August 4, 2022 AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC AVEO Oncology Announces Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA® (tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced (R/R) Renal Cell Carcinoma (RCC) Patients AVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO Annual Meeting AVEO Oncology Announces Participation at the H.C. Wainwright Global Investment Conference AVEO Oncology Reports First Quarter 2022 Financial Results AVEO Oncology to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022 AVEO Oncology Reports Full Year and Fourth Quarter 2021 Financial Results AVEO Oncology to Announce Full Year 2021 Financial Results and Host Conference Call and Webcast on March 14, 2022 Actinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors AVEO Oncology to Present Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Third- and Fourth-Line Renal Cell Carcinoma AVEO Oncology Announces Participation at the 11th Annual SVB Leerink Global Healthcare Conference AVEO Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2α Inhibitor, and FOTIVDA® (tivozanib) for the Treatment of Advanced Clear Cell Renal Cell Carcinoma AVEO Oncology Highlights Recent Progress and 2022 Outlook AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate Ficlatuzumab and ERBITUX® (cetuximab) in Patients with Recurrent or Metastatic HNSCC AVEO Oncology Announces Participation at the H.C. Wainwright Virtual BioConnect 2022 Conference AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update AVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021 AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by the U.S. FDA for the Treatment of Relapsed or Recurrent Head and Neck Squamous Cell Carcinoma AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences AVEO Oncology Reports Second Quarter 2021 Financial Results and Provides Business Update AVEO Oncology to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021 AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma AVEO Oncology to Host Key Opinion Leader Webinar on Ficlatuzumab in Head and Neck Squamous Cell Carcinoma AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update AVEO Oncology to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 10, 2021 AVEO Announces Appointment of Kevin Cullen, M.D., to Its Board of Directors AVEO Oncology Announces Addition of FOTIVDA® (tivozanib) into National Comprehensive Cancer Network Clinical Practice Guidelines AVEO Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares AVEO Announces Pricing of $48.0 Million Public Offering of Common Stock AVEO Announces Proposed Public Offering of Common Stock AVEO Oncology Announces U.S. Commercial Availability of FOTIVDA® (tivozanib) for the Treatment of Adult Patients With Relapsed or Refractory Advanced Renal Cell Carcinoma Ahead of Previous Guidance AVEO Oncology Reports Full Year 2020 Financial Results and Provides Business Update AVEO Oncology to Regain Ex-North American Rights to AV-203 AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) in Pivotal Phase 3 TiNivo-2 Trial in IO Relapsed Renal Cell Carcinoma AVEO Oncology Announces Drawdown of $20 Million Tranche Under Hercules Debt Facility AVEO Announces Appointment of Mike Ferraresso to Chief Commercial Officer AVEO Oncology Announces U.S. FDA Approval of FOTIVDA® (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences Conference AVEO Oncology Announces Participation at the 2021 SVB Leerink Global Healthcare Conference AVEO Oncology Announces Presentation of Key Subgroup and Quality of Life Analyses from the Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma AVEO Oncology Announces Commitment for an Incremental $10 Million Loan in Addition to Current Tranched, $35 Million Debt Facility with Hercules Capital AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma AVEO Oncology Highlights Recent Progress and 2021 Outlook AVEO Oncology Announces Participation at Two Upcoming Investor Conferences AVEO Oncology Announces Webcast of Presentation at the 39th Annual J.P. Morgan Healthcare Conference AVEO Oncology to Present at the Stifel 2020 Virtual Healthcare Conference AVEO Oncology Announces Appointment of David W. Crist as Vice President of Sales